Feb 7, 2022, 14:35 by Bob Davis

ASAM’s newly released 2022-2025 Strategic Plan builds upon ASAM’s existing mission to be the physician-led professional community for those who prevent, treat, and promote remission and recovery from the disease of addiction, and to provide resources for continuing innovation, advancement, and implementation of addiction science and care.

Feb 3, 2022, 09:00 by Bob Davis

Chinazo Cunningham, MD, MS, FASAM, commissioner of NYS Office of Addiction Services and Supports (NYS OASAS) in Albany, New York, is this year’s recipient of ASAM’s Brinkley Smithers Distinguished Scientist Award. The award is given in recognition of a physician’s highly meritorious contributions in advancing the scientific understanding of addiction, its prevention, and treatment options.

Jan 28, 2022, 15:51 by Bob Davis

On January 26th, the Minnesota Society of Addiction Medicine (MNSAM) sent a letter to Representative Robert Bierman outlining concerns with his bill: HF 1851. This legislation would reform the criteria for treating intractable pain with prescription opioids, including revising the definition of what constitutes intractable pain and palliative care.

Jan 26, 2022, 02:00 by Bob Davis

On January 26th, ASAM submitted a comment letter to CMS’s proposed rule Patient Protection and Affordable Care Act (ACA); HHS Notice of Benefit and Payment Parameters (the “NBPP 2023 Rule”).

Jan 24, 2022, 14:15 by Bob Davis

ASAM and ten other health professional associations have called for the FDA to immediately and fully retract its buprenorphine Drug Safety Communication of January 12, 2022. In their letter, the signatories maintain that the communication is based on “flawed analysis.”

Jan 10, 2022, 10:34 by Bob Davis

On January 7th, the Illinois Society of Addiction Medicine (ISAM) sent letters to Governor J.B. Pritzker and Attorney General Kwame Raoul urging them to immediately adopt the “Principles for the Use of Funds From the Opioid Litigation.”

Jan 5, 2022, 09:58 by Bob Davis

In December 2020, the President signed the Consolidated Appropriations Act (CAA), 2021, which made fiscal year (FY) 2021 appropriations for the federal government and added 1,000 additional Medicare-supported residency slots starting in FY 2023.

Jan 3, 2022, 08:21 by Bob Davis

Dr. Wiegand serves as Associate Professor of Emergency Medicine and the Director of Addiction Toxicology and the Toxicology/Addiction Consult Service at Strong Memorial Hospital and the University of Rochester Medical Center. He started treating addiction 20 years ago and has since worked to bridge the fields of addiction medicine and medical toxicology. His efforts to do so contributed to him winning ASAM’s Annual Award, which he said he is honored to receive.

Dec 21, 2021, 15:24 by Bob Davis

On December 20th, the New York Society of Addiction Medicine (NYSAM) sent a letter to Governor Kathy Hochul urging her to sign A2030/S649. This legislation would remove prior authorization on all forms of medication for addiction treatment (MAT) within the state’s Medicaid program.

Dec 6, 2021, 16:31 by Bob Davis

On December 2nd, ASAM sent a letter to the Food and Drug Administration (FDA) responding to their request for feedback in reevaluating the voluntary status of the Opioid Analgesics (OA) Risk Evaluation and Mitigation Strategy (REMS) program. Currently, FDA is considering extending the REMS program to become a mandatory course for all opioid prescribers.

Dec 6, 2021, 14:51 by Bob Davis

“I'm honored and gratified that the work I've done has been impactful enough to get that kind of recognition,” said Dr. Mee-Lee, president of DML Training and Consulting. “It’s a real honor and privilege to have been chosen.”

Dec 6, 2021, 14:11 by Bob Davis

Penny S. Mills, MBA, former Executive Vice President/CEO of the ASAM receives the 2021 James H. Tharp Award. This annual trust award is given to the individual that has contributed most toward the solution of the problem of alcoholism.

Dec 2, 2021, 09:21 by Bob Davis

ASAM launches its first-ever massive open online course (MOOC) on addiction medicine, open to a global audience including the public, patients, and providers.

Dec 1, 2021, 14:57 by Bob Davis

OHSAM sent a letter to members of the Senate Committee on Small Business and Economic Opportunity opposing SB 261. SB 261 would update the regulatory framework governing the state’s medical cannabis program.

Nov 19, 2021, 02:00 by Bob Davis

Nation’s leading association of addiction medicine physicians and other clinicians commend inclusion of provisions that would improve equitable coverage and access to comprehensive addiction care, and reduce the shortages of, and strengthen, the addiction treatment workforce

Nov 17, 2021, 14:50 by Jaida Montenegro

Conversation on the Future of Science Research of Addiction Medicine with Nora Volkow, MD, Director of the National Institute on Drug Abuse (NIDA) at the National Institutes of Health (NIH), and Maureen Boyle, PhD, Chief Quality and Science Officer at ASAM.

Nov 9, 2021, 02:00 by Bob Davis

The new toolkit, authored by Manatt Health Strategies in collaboration with the American Society of Addiction Medicine and Well Being Trust, provides ways for ensuring consistent use of patient-centered addiction care across providers, payers, and patients

Nov 5, 2021, 02:00 by Jaida Montenegro

On November 5th, ASAM sent a letter to Senators Chris Murphy and Bill Cassidy in response to their request for input on policies to improve mental health and substance use disorder care.

Nov 1, 2021, 02:00 by Bob Davis

On July 1, 2020, Louis Baxter, Sr., MD, DABAM, DFASAM, watched with gratitude as a vision he helped cast became a reality. That day marked the inaugural graduation of fellows from Howard University Medical School’s new Addiction Medicine Fellowship Program. Dr. Baxter, the program’s co-founder and director, helped establish the program with the goal of providing addiction medicine services to underprivileged patients in the DC metropolitan area.

Nov 1, 2021, 02:00 by Jaida Montenegro

On November 1st, the Michigan Society of Addiction Medicine (MISAM) sent a letter to the membership of the House Committee on Health Policy in support of SB 412. If enacted, SB 412 would remove prior authorization requirements on FDA-approved medications for opioid use disorder within the state’s Medicaid program.